# A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

> **NCT04869228** · PHASE3 · TERMINATED · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 380 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** GT0918 tablets or placebo

## Key facts

- **NCT ID:** NCT04869228
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-04
- **Primary completion:** 2022-09-02
- **Final completion:** 2023-08-02
- **Target enrollment:** 380 (ACTUAL)
- **Why stopped:** This decision is made on changing the development strategy of GT0918 to adapt ever-changing COVID-19 pandemic management globally.
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04869228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04869228, "A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04869228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*